|
|
||||||||


* Departamento de Immunobiologia, Instituto de Biologia, Universidade Federal Fluminense, Niteroi, Brasil; and
Departamento de Imunologia, Instituto de Microbiologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brasil
We show in this study that long-term tolerance to allogeneic skin grafts can be established in the absence of immunosuppression by the combination of the following elements: 1) augmenting the frequency of regulatory CD4+CD25+ T cells (Treg) and 2) presentation of the allogeneic stimuli through linked recognition of allo- and self-epitopes on semiallogeneic F1 APCs. BALB/c spleen cells enriched for CD4+CD25+ T lymphocytes were transferred either to BALB/c nu/nu mice or to BALB/c nu/nu previously injected with F1(BALB/c x B6.Ba) spleen cells, or else grafted with F1(BALB/c x B6.Ba) skin (chimeric BALB/c nu/nu-F1). Chimeric BALB/c nu/nu-F1 reconstituted with syngeneic CD25+-enriched spleen cells were unable to reject the previously transferred F1(BALB/c x B6.Ba) spleen cells or F1(BALB/c x B6.Ba) skin grafts, and a specific tolerance to a secondary B6 graft was obtained, with rejection of third-party CBA grafts. BALB/c nu/nu mice reconstituted only with syngeneic CD25+-enriched spleen cells rejected both B6 and CBA skin grafts. In contrast, when chimeric BALB/c nu/nu-F1 were reconstituted with spleen populations comprising normal frequencies of Treg cells, the linked recognition of allo and self resulted in breaking of self tolerance and rejection of syngeneic grafts, strongly suggesting that linked recognition works in both directions, either to establish tolerance to allo, or to break tolerance to self, the critical parameter being the relative number of Treg cells.
This article has been cited by other articles:
![]() |
G. Yang, A. Liu, Q. Xie, T. B. Guo, B. Wan, B. Zhou, and J. Z. Zhang Association of CD4+CD25+Foxp3+ regulatory T cells with chronic activity and viral clearance in patients with hepatitis B Int. Immunol., February 1, 2007; 19(2): 133 - 140. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |